Adagrasib — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

3 Recruiting

6 Completed trials

4 Sponsors

19 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 3 Phase II/III: 1 Phase II: 3 Phase I/II: 2

Oversight events:

6 temporary halts 12 corrective measures across 4 trials

View oversight register →

Indications tested

Non-small cell lung cancer 5 Non-small cell lung cancer metastatic 3 Colorectal cancer metastatic 1 Non-small cell lung cancer stage IV 1 Non-small cell lung cancer recurrent 1

Sponsors using this IMP

Mirati Therapeutics Inc. 5 Bristol-Myers Squibb Services Unlimited Company 2 ETOP IBCSG Partners Foundation 1 Incyte Corp. 1

All trials

9 total

Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting

2023-503523-25-00 Phase II 9 countries Mirati Therapeutics Inc.
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Phase III 15 countries Bristol-Myers Squibb Services Unlimited Company
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Phase II/III 19 countries Mirati Therapeutics Inc.
A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended

2023-503714-77-00 Phase II 6 countries Mirati Therapeutics Inc.
ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw… Ended

2023-510463-35-00 Phase II 5 countries ETOP IBCSG Partners Foundation
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Phase III 15 countries Mirati Therapeutics Inc.
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Phase III 14 countries Mirati Therapeutics Inc.
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended

2023-503223-26-00 Phase I/II 3 countries Incyte Corp.
Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended

2023-505070-15-00 Phase I/II 5 countries Bristol-Myers Squibb Services Unlimited Company

Showing 1–9 of 9 trials

← All drugs A–Z